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Highlights 
We developed a handheld device and a time course method for fluorescence imaging 
The device can be used to study PpIX formation in healthy and diseased skin  
PpIX fluorescence grows throughout the 3 hours prior to treatment  
The fluorescence intensity varies between diagnoses and individuals 
The fluorescence depends on the body site, possibly due to differences in temperature 
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Abstract 
Background 
Topical Photodynamic therapy (PDT) is an effective treatment for superficial non-melanoma skin cancers 
(NMSC) and dysplasia. During PDT light activates the photosensitiser (PpIX), metabolised from a topical 
pro-drug. A combination of PpIX, light and molecular oxygen results in inflammation and cell death. 
However, the outcomes of the treatment could be better. Insufficient biosynthesis of PpIX may be one of 
the causes of incomplete response or recurrence. Measuring surface fluorescence is usually employed as 
a means of studying PpIX formation. The aim of this work was to develop a device and a method for 
convenient fluorescence imaging in clinical settings to gather information on PpIX metabolism in healthy 
skin and NMSC with a view to improving PDT regimes. 
Methods 
A handheld fluorescence camera and a time course imaging method was developed and used in healthy 
volunteers and patients diagnosed with basal cell carcinoma (BCC) and actinic keratosis (AK). The 
photosensitiser (precursor) creams used were 5-aminolaevulinic acid (ALA; Ameluz®) and methyl 
aminolevulinate (MAL; Metvix®). Pain was assessed using a visual analogue score immediately after the 
PDT. 
Results 
Fluorescence due to PpIX increases over three hours incubation in healthy skin and in lesional BCC and 
AK. Distribution of PpIX fluorescence varies between the lesion types and between subjects. There was no 
significant correlation between PpIX fluorescence characteristics and pro-drug, diagnosis or pain 
experienced. However, there was a clear dependence on body site  
Conclusion 
The device and the method developed can be used to assess the characteristics of PpIX fluorescence, 
quantitative analysis and time course. Our findings show that body site influences PpIX fluorescence which 
we suggest may be due to the difference in skin temperature at different body sites.  
Keywords: PDT; Fluorescence; Protoporphyrin IX; Time course imaging; Handheld camera. 
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Introduction 
Topical Photodynamic therapy (PDT) has been widely used in dermatology for the treatment of superficial 
non-melanoma skin cancer (SNMSC) and dysplasia with overall 70-90% clearance rates1,2,3. There are 
British and International Guidelines for the use of PDT in these conditions 1,2. The most common diagnoses 
treated by PDT are superficial basal cell carcinoma (sBCC), Bowen’s disease (BD), and actinic keratosis 
(AK)1,2,3. AK is a pre-malignant skin condition arising as a consequence of chronic sun exposure and if left 
untreated can progress to squamous cell carcinoma (SCC)4. Bowen’s disease is carcinoma in situ and can 
again progress to invasive SCC.  It commonly occurs on the lower legs. BCC is the commonest skin 
cancer and superficial lesions are often low risk but multiple. PDT is an effective treatment modality for 
large, multiple, superficial, low risk tumours, field carcinogenesis or dysplasia, as well as in cases when 
repeated treatments are needed3 such as immunosuppressed patients, including organ transplant 
recipients5. AK and sBCC respond better to PDT than nodular BCC, arguably due to the fact that the pro-
drug used is taken up and metabolised more efficiently in the superficial layers of skin than in deeper 
layers6. PDT results in excellent cosmetic outcomes, and healing1,2. However, results could be improved 
and based on our Scottish experience, 26% of the lesions require more than one cycle of treatment3. 
During treatment the pro-drug is applied topically (5-aminolaevulinic acid (ALA), Ameluz® or methyl 
aminolevulinate (MAL), Metvix®) to the lesion.  The pro-drug is taken up and it metabolises to 
photosensitiser (PpIX) selectively in abnormal cells, reaching higher concentrations in lesions7. Light 
(centred at 630 nm, 75 J/cm2 in our practice, although 37-150 J/cm2 may be used) is applied to excite PpIX 
from the ground state. The absorption of light leads to a singlet state that can undergo intersystem crossing 
to a long-lived triplet state which can in turn excite molecular oxygen leading to the generation of singlet 
oxygen and other reactive oxygen species (ROS) that induce oxidative stress and cell death8. Alternatively 
the singlet state of PpIX can decay back to the ground state resulting in fluorescence8. Fluorescence is 
therefore an indicator of the concentration of PpIX in tissue and can be used in PDT diagnostics and 
clinical research8,9. The efficacy of PDT depends on the combination of the three key treatment 
parameters: PpIX distribution, molecular oxygen and light delivery10.  
Thus, although PDT is widely and extensively used the response to the treatment could be improved. One 
of the causes of incomplete response or recurrence to PDT may be insufficient accumulation of PpIX 
throughout the diseased tissue11,12,13. An optimal concentration of PpIX after application of ALA as pro-drug 
has been reported to be at six hours and with the full incubation period being 24 hours in that study14. PpIX 
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concentration increases and reaches a plateau in both BCC and AK lesions after 13 hours of continuous 
application of MAL cream15. However, the recommended time to start the treatment is 3 hours1,2. Yet, there 
is a limited information about PpIX metabolism at shorter periods of time14,15, 16. Our work aims to develop 
improved instrumentation for detecting PpIX and apply it to filling these gaps in the knowledge about PpIX 
building-up during the first three hours from the application of the topical pro-drug. This information could 
potentially be used to optimise treatment parameters. In addition, we aimed to establish if there were any 
distinct fluorescence patterns for healthy skin, AK and BCC lesions, or differences between the pro-drugs. 
There are various methods of estimating PpIX accumulation in skin. One of the simplest ways is to use 
Wood’s lamp for visual assessment and grading of surface fluorescence of PpIX before PDT. Our unit has 
previously used an optical biopsy system (OBS) consisting of a 405 nm diode laser and fibre-coupled 
spectrometer to give measurements of the fluorescence spectrum of PpIX at one point on the skin. This 
system was used to study the photobleaching of PpIX fluorescence decay during treatment and reverse 
Monte Carlo modelling was used to learn about the PpIX distribution in skin17,18,19. Other groups have 
developed optical probes for quantitative measurement of real PpIX concentration and used it for studying 
the biosynthesis of  PpIX from ALA precursor16. Another technique is fluorescence microscopy for 
histological assessment of PpIX distribution6. There have been reports of custom built optical 
spectrometers for medical applications9,11,13,20,21,22,23,24,25. However, most of the systems are bulky and have 
not been designed for time course imaging and analysis.  
There were a few recent reports on smaller imaging systems for time course measurements [22,23,24,25,]. 
. In [22] an imaging platform based on a smartphone has similar conceptual optical design: there was an 
excitation source build as an array of LED placed around the camera with an emission filter on top of the 
camera. This device was able to image physiologically relevant concentration of PpIX in liquid TiO2 
scattering in-house made PpIX phantoms in a cuvette. The device was designed for bringing PDT in 
developing countries to reduce the cost of PDT lamps and proven to be suitable for delivering PDT dose of 
red light; the imaging was an additional modality for detecting PpIX fluorescence. In [23] an imaging 
platform based on a smartphone has some similarities of optical design: there was an excitation source 
consisting of an array of LED placed around the camera with an emission filter on top of the camera. This 
device was able to image physiologically relevant concentrations of PpIX in liquid phantoms using TiO2 
nanoparticles to give scattering. The device was designed for bringing PDT to developing countries to 
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reduce the cost of PDT lamps and proved to be suitable for delivering PDT dose of red light; the imaging 
was an additional modality for detecting PpIX fluorescence. In [24 and 25] the authors use portable 
handheld device which combines PDT treatment and imaging modalities. The imaging system is based on 
an array of 400 nm peak wavelength LED for excitation with 50 mW/cm2 optical output and 475 nm long 
pass filter. A Sony DSC-H50 colour digital was used for the imaging. Custom software written in Matlab 
was used to analyse red and green pixel values for PpIX fluorescence and auto-fluorescence 
correspondingly. In [24] 54 lesions (21 BCCs, 22 AK, and 11 seborrheic keratosis SK) were used in the 
study to establish if auto-fluorescence combined with PpIX assisted fluorescence can be used for optical 
detection of NMSC. ALA solution was applied to the lesions and the fluorescence was imaged at 15, 30, 45 
and 60 minutes in a dark room. They found noticeable differences between the autofluorescence in healthy 
and diseased skin; PpIX fluorescence increased the contrast at the lesion margins. In the following study 
[25] 8 BCC lesions on different anatomical sides were studied using MAL as PpIX precursor. PpIX 
fluorescence was imaged 3 hours after application of MAL i.e. just before PDT treatment and in addition 
immediately treatment.  These measurements were made for both the first and the second PDT treatment, 
which were performed one week apart. They found that the fluorescence was different for lesions at 
different anatomical sites; it was higher on the lip of one subject compared to the eye lid of another subject. 
The fluorescence was higher before the second PDT session. This system is one of the best available 
systems for repeated measurements of PpIX and autofluorescence. In comparison to this system, our 
system has lower excitation irradiance, 0.1 mW/cm2 and the illumination is synchronised with the image 
acquisition.  The synchronisation brings several benefits.  It helps to reject ambient light and improves 
signal to noise.  This in turn enables the use of low intensities (eliminating any possibility of 
photobleaching) and faster measurements.. In addition we developed a specific alignment procedure and 
camera displacement compensation image analysis to take into account operator tolerance and analyse 
identical area in all time course images with accurate referencing to the skin and the lesions. The clinical 
focus of our study was exploring the first three hours of PpIX metabolism in healthy skin and lesions to 
guide potential improvements in the treatment protocols. 
Here we report the development of a hand-held fluorescence imaging camera and its application for the 
study of PpIX fluorescence characteristics of both healthy and diseased skin.  Our portable fluorescence 
imaging camera measures the spatial distribution of surface PpIX fluorescence and allow for convenient 
quantitative clinical measurements. The excitation for the camera has the same wavelength as the OBS 
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system, 405 nm, but allows for studying fluorescence from large areas instead of a point.  Fluorescence is 
detected at 635±5 nm which is the peak of the emission of PpIX. The camera allows fast acquisition of 
normal images and fluorescence images. It can access any site on the body, has fixed focal distance, 
shielded from direct ambient light, and allows precise alignment at and referencing to the study area during 
the time course measurements. We have used the camera in a small study on healthy volunteers and 
patients with AK and BCC lesions using topical ALA (Ameluz™) and methyl aminolevulinate (Metvix). Here 
we report on the results on PpIX accumulation during three hours of incubation from the application of the 
pro-drugs and discuss the limitations and clinical relevance of PpIX fluorescence diagnostics. We introduce 
a few improvements to fluorescence imaging and analysis such as easy access to the patient, the 
possibility of carrying out the experiment with dimmed lights, accurate referencing of the fluorescence 
images to the lesion, and an image processing procedure to compensate for displacement of the camera . 
This work is a first clinical attempt to use fluorescence imaging for studying PpIX formation in NMSC in a 
time course. Finally we discuss whether there is a correlation between fluorescence and pain, the type of 
photosensitiser pro-drug and the diagnosis and speculate on the effect of temperature at different body 
sites. 
Methods 
Fluorescence imaging system 
Fluorescence was imaged using a custom built camera which was developed at the University of St 
Andrews and built as a prototype device. As the device is not CE marked, it was examined for electrical 
safety, optical output, allergic reactions and infection control and approved for the research at the 
Photobiology Unit, Ninewells hospital by the Instrumentation Department at Ninewells hospital and Medical 
School. The device consists of a Lumenera LM075M CCD camera which connects to and is powered from 
a laptop via a USB 2.0 interface. An optical lens with a tuneable focal length and an aperture is mounted to 
the camera; the focus is set to 8.5 cm and checked before each experiment. Once it is set it does not 
change during the experiment. After a normal image of the skin was acquired under 405 nm illumination, a 
threaded Thorlab interference band pass filter, FL635 with central wavelength (CWL) of 635±2 nm and full 
width at half maximum (FWHM) of 10±2 nm was attached to the top of the lens to detect only the peak of 
the PpIX emission spectrum. 
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The illuminator for the camera, which serves as an excitation source for PpIX and illumination for 
monochromatic images of the skin, is a ring of 16 low power 405 nm LEDs mounted on a custom made 
round shaped printed circuit board (PCB) with an opening in the middle for the lens. The illuminator is 
powered from a 9 V battery connected to a MOSFET switch and controlled by a USB 2.0 development 
module FTDI UM245R which turns the switch on and off. The illuminator is connected to a laptop via a 
USB 2.0 cable. The illumination and the camera are controlled via a simple graphical user interface written 
in Matlab. The exposure time for normal images is 0.1 ms, fluorescence images are taken with 16.0 ms 
exposure. The illumination is pulsed when an image is acquired; the duration of the pulse depends on the 
acquisition time. The optical output power was measured at a distance of 8.5 cm and was found to be 0.1 
mW/cm2. UV, UVA and blue light exposure limits allow using the device without any special precautions as 
long as the device is not placed directly on the unprotected eye. The camera does not become hot and is 
electrically and optically safe. 
A custom casing was designed to contain the illuminator, the battery, and the camera; it has a shielded 
rectangular tube which provides fixed focal distance to the skin site and easy alignment to the study area. 
The casing was designed in Rhino 3D CAD software and printed with a RoboSavvy MakerBot® 
Replicator® desktop 3D printer using MakerBot® polylactide (PLA) bio-thermoplastic filament. The material 
for the casing is inert and is used as a stand-off, not in contact with the skin – the device is placed on a 
disposable reference frame made of laminated paper; this should eliminate the possibility of causing any 
allergic reactions. The casing has been designed to minimise infection traps, is “wipe clean” and a 
decontamination protocol has been provided in the standard operation procedure (SOP).  The illuminator 
and camera assembly is shown on the right of figure 1.  
The casing was designed to exclude most ambient light so that experiments could be conducted with 
dimmed lights on. There are alignment marks at the end of the casing’s tube which correspond to the 
alignment marks of the reference frame so that the same area can be measured each time during a time-
course experiment. The marking for the reference frame is printed on a standard white office paper, a 
fluorescence contour is then drawn using an orange fluorescent marker pen, and the frame was laminated. 
The frame does not dissolve in any solvents used in the creams, or skin secretions. Once fixed to the skin 
with a tape, it provides a stable reference for repeated imaging of the study site. The whole set up including 
computer and accessories fits on top of a small hospital trolley (Fig. 1). 
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Validation of the system using tissue-simulating phantoms, standard fluorescent solutions and in-vivo 
The camera was tested by imaging Coproporphyrin standard solution, in house made PpIX solid 
fluorescence phantoms, and PpIX fluorescence from healthy skin.  The results were compared with 
spectral measurements taken with the optical biopsy system (OBS). The base for the phantoms was room 
temperature vulcanised silicone polymer which has similar refractive index to skin.  Alumina powder was 
added to mimicking the scattering properties of the skin26 and PpIX added to give fluorescence. Two parts, 
A and B of RHODORSIL RTV 141 polymer were mixed in a 1:10 ratio, 4% of alumina scattering powder 
was added to the mixture, and Protoporphyrin IX P8293 - ≥95% from SIGMA-ALDRICH were dissolved in 
Methanol. A range of PpIX concentrations of 10, 20, 40, 80, 160, 320 and 640 nM in the phantoms was 
made for the test. PpIX solution was thoroughly mixed with the silicone polymer and alumina powder and 
left at room temperature to vulcanise. The phantoms normally vulcanise and the methanol evaporates after 
72 hours. We found our camera could successfully image PpIX fluorescence from all the test samples, and 
then proceeded to image fluorescence from NMSC of two patients, P1 with a BCC lesion and P2 with one 
AK and two BCC lesions in order to select the appropriate settings for the device.  
Pilot clinical trials – study design 
A clinical study was conducted to determine the applicability of this device for fluorescence imaging 
diagnostics, to gather fluorescence images in normal skin and in diseased tissue from different lesions and 
to fill gaps in knowledge about PpIX fluorescence and time course using two types of pro-drugs and two 
types of lesions – Ameluz® and Metvix® administered for BCC and AK. The study was approved by the 
University of St Andrews Teaching and Research Ethics Committee (UTREC) Ref.: PA10783. The study 
was conducted in compliance with good clinical practice (GCP) laid down in The Medicines for Human Use 
(Clinical Trials) regulations 2006 No. 1928. There was no requirement for clinical trial authorisation (CTA) 
from the UK Medicines and Healthcare products Regulatory Agency (MHRA) as the imaging device was 
assessed by Professor George Corner, NHS Tayside Head of Instrumentation, as being a prototype and 
was fit for use in this study alone. The study was also approved by the East of Scotland Research Ethics 
Service (EoSRES) Committee (REC Ref # 13/ES/0151). Study subjects were identified and recruited from 
the Photobiology Unit healthy volunteer panel and patient referrals to the Photobiology Unit for 
photodynamic therapy. Written informed consent was obtained from all subjects before any study-specific 
activity commenced.  
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The inclusion criteria for the healthy volunteers were the following: age 18 years and over (age matched to 
patient cohort as far as practicably possible), both males and females, capable of giving informed consent 
and able to understand and adhere to the protocol’s requirements and having no evidence of active skin 
disease. The exclusion criteria were the following: anyone with known allergy to Metvix or Ameluz or 
known to have a light sensitivity disorder. The inclusion criteria for the patients were the following: patients 
presenting with superficial non-melanoma skin cancer (BCC) and dysplasia (AK) of 18 years age and over, 
both males and females, capable of giving informed consent and able to understand and adhere to the 
protocol’s requirements. The exclusion criteria for the patients were: patient's skin lesion had had previous 
treatment within the last four months, patients who were unable to give informed consent, patients with 
known allergy to Metvix or Ameluz or known to have a light sensitivity disorder. The information sheets 
were given at least a day before the study and informed consent was taken on the day of the study. 
The study included 10 healthy volunteers: in five Metvix was used as pro-drug and the other five received 
Ameluz gel topically. The skin at the study area was cleaned with ethanol wipes and left to dry before the 
measurements. From our previous experience we have seen that PpIX metabolism varies at different body 
sides27. ALA and MAL as PpIX precursors seem to metabolise to give higher concentrations of PpIX on the 
inner forearm, with lower concentrations on the lower leg. For the healthy volunteers we selected the 
middle of the back as the site for study as it accumulates PpIX at a medium concentration - in between that 
of the forearm and lower leg – and so is the best choice for a baseline.  
The patient cohort aimed to include 15 patients: five with biopsy confirmed BCC lesions administered 
Metvix PDT, five AK diagnoses treated with Ameluz PDT, and another five AK diagnoses treated with 
Metvix PDT. Due to the timescale of the project the study was terminated after 13 patients meaning that we 
had two fewer patients than planned for AK treated with Metvix PDT. White light images were taken of 
each subject before the experiments. The lesions were located on different body sites and varied in size. If 
the size of a lesion was larger than the size of the reference frame, 3.1 cm x 2.4 cm, we selected a small 
area for the study and the rest of the area was prepared and treated routinely. The whole area was 
prepared using gentle curettage without a local anaesthetic (Stiefel™ring curette) to remove all the crusting. 
The corners for the reference frame were marked with a marker pen; topical pro-drug was applied to the 
area of the lesion and a 5 mm rim of normal tissue. TegadermTM film and  Mepore™ occlusive dressing 
was prepared to cover the lesion, but leaving the study area open (Fig. 2). The reference frame which has 
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alignment marks corresponding to the alignment marks at the tube of the camera system, and a bright 
fluorescent contour, which will appear as a saturated white line on fluorescence images for processing the 
images, was fixed on top of the occlusive dressing with a tape.  
A normal monochromatic image of the lesion was taken, then a band pass filter was inserted and 
background fluorescence was imaged. The cream was then applied with a wooden spatula, a TegadermTM 
occlusive small dressing was placed on top of the reference frame (Fig. 2 c). The small dressing could be 
easily lifted up and put back again between the readings. Fluorescence was imaged every 10 minutes. 
Because Metvix cream is opaque, for each measurement we removed the cream and then re-applied it. 
For consistency we followed the same procedure for Ameluz gel even though it is transparent and does not 
affect the imaging. 
The measurement procedure was the following. There were two timers, one set for nine minutes, the other 
for one minute. One minute was allocated to take the dressing off, wipe the cream, take a fluorescence 
image, and put the cream and the dressing back on. When nine minutes had passed we started the one 
minute timer. During this minute the small dressing was lifted up, the cream was scraped off with a wooden 
spatula, the remaining cream was wiped off with a cotton wipe, a fluorescence image was taken; the 
topical pro-drug from the spatula was applied back on (when this was used up, a small amount of fresh 
cream or gel was added to keep the area covered all the time) and the small dressing was put back on. 
After the one minute timer had elapsed, the nine minute timer was started again. The measurements were 
repeated 18 times during three hours. After three hours the cream was removed, fluorescence was visually 
assessed and scored using a Wood’s lamp as an excitation source and routine PDT was delivered (LED 
light sources, 630 nm, 75 J/cm2)17. After the treatment had been completed the patients were given a form 
to assess their pain level on a visual analogue score (VAS) scale with a score from 0 to 10 corresponding 
to no pain for 0 points and unbearable ‘worst pain imaginable’ pain for 10 points.  
Image processing and analysis 
The reference frame has a highly fluorescent contour – an orange rectangle at the inner edges (Fig. 2c), 
which is seen as a saturated line in all the fluorescence images. This saturated rectangle helps to select 
the same area on each image for further analysis. The images were acquired, processed and analysed in 
MATLAB 2014, Image Acquisition, Image Processing and Computer Vision System Toolbox. The 
fluorescent alignment rectangle allowed us to compensate for any displacement of the camera between 
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readings We used the random sample consensus (RANSAC) geometrical transformation to detect 
matching points on the fluorescent alignment contour between the reference image (normally a 
background image) and the series of 18 fluorescence images. The fluorescence images were 
reconstructed - rotated and centred to correspond to the position of the background image. After that the 
fluorescent contour was cropped out and background fluorescence subtracted. The initial size of the image 
was 640 x 480 pixels which corresponded to  3.1 mm x 2.4 mm; it was cropped to 540 x 380 pixels leaving 
67% of the area for further analysis. This completed pre-processing of the images and prepared them for 
fluorescence analysis. Various regions of interest (ROIs) were selected and an integrated fluorescence 
was calculated over the ROIs. The size of the ROIs varied depending on the size of uniform peak 
fluorescence region. The smallest ROI was 25 x 38 pixels for P004 subject and the largest was 73 x 86 
pixels for P013. Fluorescence was correlated to the study area.  
Fluorescence homogeneity was calculated in the ROIs and over the whole image at 180 min from the 
application of the creams. The fluorescence value and pixel indices for local minimum and local maximum 
for ROI and global minimum and global maximum for the whole image were identified. In order to reduce 
numerical noise 5 pixel values were averaged at the minima and maxima. The homogeneity was calculated 
as 1-({global, local} max- {global, local} min) / local_mean, %. 
Statistical data analysis 
The statistical significance for the fluorescence time course between healthy volunteers Ameluz and Metvix 
groups, AK Metvix, AK Ameluz, BCC Metvix, body sites groups (the head & the neck vs lower leg & feet, 
trunk & hands) groups were estimated by t-test for two-sample assuming unequal variances. 
Results  
Camera validation tests 
Fig. 3 shows emission spectra measured with the OBS system and fluorescence images from the 80 nM 
PpIX phantom, coproporphyrin solution in HCl, and PpIX fluorescence from a healthy volunteer three hours 
after application of topical Ameluz gel in an aluminium Finn® chamber for patch tests. We have compared 
the emission spectra to the fluorescence images taken with the camera. PpIX phantoms have a typical 
emission peak at 633 nm and a slightly elevated second peak at 700 nm. Coproporphyrin has two peaks at 
594 and 653 nm. PpIX fluorescence from the volunteer (after application of Ameluz) has peak at 635 nm 
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which corresponds to the transmission of the band pass filter. Our camera has high selectivity for 635 nm 
PpIX emission and rejection of other wavelengths, which is why PpIX fluorescence formed from Ameluz 
from the healthy volunteer appears brighter on the fluorescent images than the 80 nM PpIX solid phantom 
or Coproporphyrin solution. Our current procedure does not take account of differences in the optical 
properties of skin in different individuals; so we are not able to extract real concentrations of PpIX from our 
measurements. However, all of our subjects have skin types I-III which do not have drastic variation in 
melanin concentration. This in principle should allow us to compare relative PpIX fluorescence 
measurements across the individuals.  
Preliminary data gathering from BCC and AK lesions 
Two patients, subject P1 with a BCC lesion and subject P2 with two BCC and one AK lesion, were imaged 
prior to finalising the clinical study design in order to select appropriate camera settings. The BCC lesion 
from subject P1 was imaged three hours after application of Metvix before first and second PDT treatments 
separated one week apart (Fig. 4). We have observed a reduction in fluorescent area and a drop in 
fluorescence intensity which shows tumour response to the first PDT treatment and the relevance of using 
the device for fluorescence diagnostics. 
Clinical study 
Healthy volunteers: Ameluz and Metvix PpIX fluorescence time course 
Our study protocol included 10 healthy volunteers: Metvix® cream was applied to five and Ameluz™ gel to 
the other five. The Metvix® volunteers group had 6 volunteers instead of the planned 5 as one of the 
volunteers developed almost undetectable fluorescence. The study site for all of the volunteers was the 
middle of the back avoiding the paravertebral regions. Fig. 5 shows the fluorescence time course 
calculated by integrating over the whole area of the images. Background fluorescence was subtracted and 
the readings normalised to the maximum of the camera. Our findings suggest that there is no obvious 
difference between Ameluz and Metvix in the resulting fluorescence time courses; Ameluz and Metvix 
groups are not statistically significantly different, the p-value was found to be 0.3 in two sample t-test with 
unequal variances. Although there is variation between subjects, concurring with previous findings27,28. 
PpIX fluorescence was still increasing after three hours incubation. 
Fluorescence from eight out of ten volunteers was mostly uniform. Two out of ten volunteers showed 
slightly spotted patterns which however did not have an obvious correlation to the skin structure.  
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Patients: Ameluz- and Metvix-induced PpIX fluorescence from BCC and AK lesions at different body sites 
The results from 13 patients showed variation in fluorescence patterns between the subjects and between 
lesions. Some of the lesions with non-hyperkeratotic surfaces and well defined margins had uniform 
fluorescence over the lesions. Fluorescence started to develop at a smaller area inside visible margins and 
became visible to the device after about 60 minutes from the application of the pro-drugs (Fig. 6 d). It 
continued to grow at different rates over different areas on the lesions. For example, in the case of subject 
P010 an area highlighted with red dashed rectangle (Fig. 6) showed the highest PpIX fluorescence. Such 
hot spot regions were selected for calculations of an integrated fluorescence time course. In six cases the 
fluorescence extended beyond the visible borders. However in the other seven cases the fluorescence was 
evident in only some parts of lesions and in many cases fluorescence developed at areas of the skin that 
were outside the apparent extent of the lesion, possibly highlighting sub-clinical disease.  
On average for 12 patients the fluorescence of the lesion was homogeneous with more than 75 % 
homogeneity in the ROIs; and for one patient it was heterogeneous with homogeneity equal to 25 %. Over 
the whole image the fluorescence was heterogeneous with homogeneity less than 21 % on average for 12 
patients which indicated the contrast between the peak fluorescence in ROI and the rest of the image 
including healthy parts of the skin in cases for well-defined fluorescence patterns; the fluorescence was 54 
% homogeneous for one patient with poorly defined weak fluorescence. 
Fig. 6 b shows an overlap of the fluorescence image on a false colour scale taken after three hours of 
Metvix application and a monochromatic image of the BCC lesion. There were fluorescent areas outside 
the visible lesion at the top of the image which did not appear to have evidence of diseased skin to the 
naked eye. In the case of P005 (Fig. 7) there are two AK lesions similar in size and shape situated on the 
same foot close to each other. Both of the lesions were treated with Metvix PDT; treatment and study-
related measurements were undertaken at the same time for both lesions. One of the lesions, #4, showed 
much stronger fluorescence over a larger area than the other lesion, #1. Also from the fluorescence image 
we can see the formation of two halves of the lesion #4 correlating with lesion shape (Fig. 7 a, b). Lesion 
#1 developed much weaker fluorescence which did not correlate with the shape of the lesion. Interestingly 
pain score for both of the lesions was the same. 
In cases where there was crusting, erosion and/or bleeding after surface preparation the fluorescence 
signal could be reduced which made fluorescence diagnostics much more challenging (SI 1, SI 2). In such 
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cases the regions of interest (ROIs) for the integrated fluorescence calculations were selected avoiding 
these areas.  
An integrated fluorescence time course suggested that PpIX fluorescence continued to increase over three 
hours in all subjects. There was no obvious difference between diagnoses (AK or BCC), nor the pro-drugs 
(Ameluz or Metvix); p-values for AK Ameluz and AK Metvix group was 0.16, p-values for AK Metvix and 
BCC Metvix was 0.18. Nor was there a correlation between PpIX fluorescence and pain experienced, the 
correlation coefficient was -0.18, (SI 4). However, there was an obvious dependence for with body sites. 
The p-value for the group of the head & the neck vs the lower leg & the feet was 0.0003, and between the 
group of the head & the neck vs trunk & the hands was 0.001. There was no significant statistical 
difference between the group of the lower leg & the feet compared to the group of trunk & the hands, p-
value was 0.12. Fluorescence was obviously higher at the head and the neck than on the lower leg, the 
foot, the hand and the back.  
Discussion 
PpIX fluorescence patterns of AK and BCC lesions and where PpIX fluorescence diagnostics and display 
of NMSC is useful  
It has been reported that PpIX fluorescence does not have absolute correlation to PDT outcomes11,12, yet it 
has been successfully used to detect early stages of malignant changes in the skin29,9,30. Measurement of 
fluorescence is the most widely used method employed for non-invasive in-vivo imaging of PpIX 
metabolism, which in turn may be used as a surrogate to optimise PDT parameters.  
The fluorescence patterns which we observed so far are consistent with previous reports. In a proportion of 
the subjects in our study fluorescence developed within visible tumours with definition at tumour margins 
similar to that reported [20,13]. The cases where fluorescence developed in the areas close to the lesions 
but without any visible evidence of malignant skin disease is supportive of the pick up of subclinical 
disease and agrees with the study on wide field PpIX fluorescence imaging for early stage NMSC 
diagnostics29.  
Some of the studies report cases without obvious fluorescence but yet response to PDT11,12. We also saw 
cases with weak fluorescence. However, our device still was able to detect it and its development over 
17 
 
time. We analysed the time course over hot spot ROIs, and could precisely relate the ROIs on the 
fluorescence images to the shape of the lesions. Our method does not fully resolve the problem of reduced 
fluorescence detection in the presence of bleeding, crusting and erosion, which complicates fluorescence 
diagnostics. Yet, it offers flexibility in selecting ROI and accuracy in correlating it to the lesions which may 
be useful for some studies. 
PpIX fluorescence correlation to the body sites: does skin temperature influence PpIX metabolism at 
different body sites? 
Our results showed higher fluorescence on the head and the neck compared to the lower leg (Fig. 8). This 
agrees with our previous study on PpIX fluorescence from healthy skin at different body sites which 
showed lower fluorescence at the lower leg27,28. We speculate that this may be due to the difference in the 
temperature at different body sites. It is also possible that the higher vascularization of the head and neck 
compared to the body extremities plays a role. It has been reported that PpIX metabolism is faster at 
higher temperatures31,32. Skin temperature varies at different body sites and can be displayed with infrared 
imaging cameras33 [http://www.rnhrd.nhs.uk/page/92]. Typical temperatures of the head and the neck have 
found to be 35-37°C34,35, the lower leg and the “edge” areas of the feet and the hands have lower 
temperatures of 30-33°C. We estimated typical temperatures of healthy skin at the lesions sites using 
infrared thermal images reported in the literature (SI 5) 35,34,36 and correlated this with the fluorescence 
measurements. The body sites which typically are hotter develop higher fluorescence (Fig. 8) which 
suggests that the skin temperature may be responsible for the rate of PpIX metabolism; if this hypothesis is 
true heating up or cooling down would have a significant effect on treatment. There is evidence to show 
that cooling air to reduce pain has an adverse effect on PDT outcomes37 and increasing the skin 
temperature results in increased PpIX metabolism32,38,39. 
PpIX fluorescence correlation to the pro-drugs used and pain experienced 
There is rather conflicting evidence in the literature about pain/fluorescence correlation16,13. Our results 
suggest that there is no obvious correlation or significant statistical dependence (SI 4). One study [13] 
reported higher MAL fluorescence compared with ALA. We did not see an obvious difference between ALA 
or MAL PpIX-induced fluorescence time courses. 
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Conclusions 
A light weight hand-held fluorescence imaging camera that is easy to use in a clinical setting has been 
introduced and used in a small study of PpIX metabolism. The camera has a 405 nm illumination and PpIX 
excitation source; a removable band pass filter cantered at a 635 nm PpIX emission peak. The camera 
allows acquisition of monochromatic images of the skin under 405 nm illumination and 635 nm 
fluorescence images. Custom made bio-plastic casing is shielded from direct ambient light and allows 
carrying measurements with dimmed lights. Alignment marks on the casing and a corresponding 
disposable flexible reference frame which is fixed to the skin of a patient with a tape allows imaging and 
analysing the same area through time course study.  
We have designed a fluorescence time course imaging method and analysed results from 11 healthy 
volunteers and 13 patients. We have not seen an obvious difference in fluorescence time courses between 
Ameluz and Metvix pro-drugs used (whether in healthy volunteers or in patients) and also did not see a 
difference between BCC and AK lesions. However, there was dependence of the strength of fluorescence 
on the body site –fluorescence was lower on the lower leg and higher on the head and the neck. We 
suggest that this may be caused by lower temperature on the lower leg which may result in slower PpIX 
metabolism. Our results show that the fluorescence is still increasing three hours after application of the 
pro-drugs in both patients and healthy volunteers.  This suggests that waiting longer after applying the 
cream could increase PDT response, although loss of specificity at longer incubation periods is a potential 
concern.  
We have seen a large variation in fluorescence between subjects and lesions. There is insubstantial and 
conflicting current evidence in the literature about pain/fluorescence correlation; our results do not show a 
correlation.  
Although caution is needed in over-interpretation of the results in this small study, it is a first clinical attempt 
to undertake a time course study using this quantitative fluorescence imaging device. Our findings address 
some of the gaps in understanding of PpIX metabolism in different lesions at different body sites, using 
different pro-drugs. We hope that this will lead on to further studies, with a view to optimisation of treatment 
regimes. 
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Figure Captions 
 
Fig. 1 – The experimental set up on a small hospital trolley (the camera is on the right). a – camera 
assembly. b – illuminator. c – disposable reference frame. d – emission filter. 
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Fig. 2 – Lesion preparation procedure. a – the lesion is prepared with a curette, a small study area is 
selected, the corners of the area are marked with a marker pen, pro-drug is applied to the lesions outside 
the study area, transparent Tegaderm™ film is prepared to leave an opening over the study area. b – 
occlusive dressing is placed on the lesion leaving the study area accessible. c – the reference frame is 
fixed at the study area with a tape. A small dressing can be lifted up and put back again between the 
measurements. A wooden spatula is used to remove the cream and put it back after the measurement. d – 
the area is covered with an occlusive dressing between the measurements. 
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Fig. 3 – Camera validation on PpIX phantoms, Coproporphyrin and Ameluz PpIX fluorescence from the 
skin of a healthy volunteer. a – a photograph of PpIX solid silicone phantoms with a range of PpIX 
concentrations. b – OBS measurements of PpIX fluorescence from the phantom with 80 nM concentration 
and Ameluz PpIX fluorescence from the skin of a volunteer after 3 hours of Ameluz gel application in an 
aluminium test patch chamber. The image on the top left corner is a fluorescence image of the phantom 
taken with the camera, the image below is an image of PpIX fluorescence from the volunteer. c – OBS 
measurements of coproporphyrin fluorescence and Ameluz PpIX fluorescence from the volunteer. The 
image at the top left corner is a fluorescence image of coproporphyrin solution in a Perti dish. Left half of 
the Petri dish is covered with a piece of beam blocking paper. 
 
 
Fig. 4 – The camera validation on PpIX fluorescence from a BCC lesion using Metvix cream. a, b – 3D and 
2D surface PpIX fluorescence on a false colour scale taken after 3 hours of Metvix application before the 
first PDT treatment. c – 2D fluorescence image on the false colour scale before the second treatment (a 
week later than b). The fluorescence area and the intensity are reduced indicating the response of the 
lesion to the first PDT treatment. 
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Fig. 5 – Fluorescence time course from healthy volunteers indicating no obvious difference between 
Ameluz and Metvix metabolism in healthy skin on the middle of the back. 
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Fig. 6 – P010 – biopsy confirmed BCC lesion administered Metvix PDT: a – a white light image, b – a 
monochromatic image of the lesion taken with a 405 nm flash. The left half of the image is overlapped with 
a semi-transparent fluorescence image on the false colour scale taken at 180 minutes after Metvix 
application which helps to visualise the correlation between the lesion and the fluorescence, c – a 
monochromatic fluorescence image at 180 min of Metvix application, d – a false colour fluorescence image 
at 60 min, e – a false colour fluorescence image at 180 min. Red dashed line shows a region of interest 
which has the highest fluorescence and is used for the calculation of integrated fluorescence in the time 
course. 
 
Fig. 7 – P005 - two similar in shape and size AK lesions on the foot treated by Metvix PDT. One lesion is 
expressing much higher fluorescence than the other a, b – fluorescence images at 180 min on a 
monochromatic and a false colour scale from #4 lesion. c – a white light image, d, e – fluorescence images 
at 180 min on a monochromatic and a false colour scale from #1 lesion 
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Fig. 8 – Fluorescence time course from 13 patients indicating higher fluorescence on the head and the 
neck comparing to the lower leg. Temperatures were taken from the literature36,34,35.  
 
 
